The prognostic significance of wild type isocitrate dehydrogenase 2 (IDH2) in breast cancer by Aljohani, Abrar I et al.
Vol.:(0123456789) 
Breast Cancer Research and Treatment 
https://doi.org/10.1007/s10549-019-05459-7
PRECLINICAL STUDY
The prognostic significance of wild‑type isocitrate dehydrogenase 2 
(IDH2) in breast cancer
Abrar I. Aljohani1  · Michael S. Toss1 · Sasagu Kurozumi1 · Chitra Joseph1 · Mohammed A. Aleskandarany1 · 
Islam M. Miligy1,2 · Rokaya El Ansari1 · Nigel P. Mongan3,4 · Ian O. Ellis1 · Andrew R. Green1 · Emad A. Rakha1,2,5
Received: 18 September 2019 / Accepted: 25 September 2019 
© The Author(s) 2019
Abstract
Background Lymphovascular invasion (LVI) is a prerequisite step in breast cancer (BC) metastasis. We have previously 
identified wild-type isocitrate dehydrogenase 2 (IDH2) as a key putative driver of LVI. Thus, we explored the prognostic 
significance of IDH2 at transcriptome and protein expression levels in pre-invasive and invasive disease.
Methods Utlising tissue microarrays from a large well annotated BC cohort including ductal carcinoma in situ and invasive 
breast cancer (IBC), IDH2 was assessed at the transcriptomic and proteomic level. The associations between clinicopatho-
logical factors including LVI status, prognosis and the expression of IDH2 were evaluated.
Results In pure DCIS and IBC, high IDH2 protein expression was associated with features of aggressiveness including high 
nuclear grade, larger size, comedo necrosis and hormonal receptor negativity and LVI, higher grade, larger tumour size, 
high NPI, HER2 positivity, and hormonal receptor negativity, respectively. High expression of IDH2 either in mRNA or in 
protein levels was associated with poor patient’s outcome in both DCIS and IBC. Multivariate analysis revealed that IDH2 
protein expression was an independent risk factor for shorter BC specific-survival.
Conclusion Further functional studies to decipher the role of IDH2 and its mechanism of action as a driver of BC progres-
sion and LVI are warranted.
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Introduction
Breast cancer (BC) progression is a complex multifactorial 
process. However, the invasion machinery which is a critical 
step in progression from in situ to infiltrating tumour fol-
lowed by distant metastasis remains unclear. Deciphering 
the transcriptomics and proteomics that govern the invasive 
and metastatic cascades of BC is essential in understand-
ing the mechanisms of cancer progression. Lymphovascu-
lar Invasion (LVI) is an independent prognostic factor of 
poor outcome in invasive BC (IBC) and is a prerequisite for 
the tumour metastasis [1–4]. Understanding the molecular 
mechanisms underlying BC progression, and in particular 
LVI, and unveiling their driver molecular pathways could 
ultimately improve patient outcomes [5]. Through stringent 
bioinformatics analysis, we have previously interrogated 
transcriptomic datasets of IBC [Molecular Taxonomy of 
Breast Cancer International Consortium (METABRIC) and 
The Cancer Genome Atlas (TCGA)] for putative drivers of 
LVI [6]. Briefly, LVI positive and negative cases from these 
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cohorts were subjected to a method of weighted average dif-
ference (WAD) and subsequently differentially expressed 
genes (DEGs) were identified based on WAD rankings [7]. 
Forty-two significantly overexpressed and 57 downregulated 
genes identified in the METABRIC cohort were identified 
and validated in the TCGA cohort [8]. Wild-type Isoci-
trate Dehydrogenase 2 (IDH2) was a highly expressed gene 
associated with presence of LVI [8]. Moreover, IDH2 was 
reported to be differentially expressed between recurrent and 
non-recurrent DCIS and associated with DCIS recurrence 
and progression to invasive disease [9, 10].
IDH2 is a member of the isocitrate dehydrogenase fam-
ily that plays a key role in cellular metabolism and acts in 
the tricarboxylic acid (TCA) cycle as an NADP + consum-
ing enzyme, producing NADPH. In the reverse TCA cycle, 
when IDH2 causes reductive carboxylation of 2-oxoglutarate 
(2-OG), it consumes cell during hypoxia to survive the lower 
glucose levels [11].
Cellular energy and biosynthetic intermediates are pro-
duced by the TCA cycle, which are upregulated in metas-
tasised cancer cells. Glycolysis is also upregulated in can-
cer cells to produce biosynthetic intermediates and energy 
needed for cellular proliferation and survival. Circulat-
ing tumour cells are predisposed to anoikis as a result of 
impaired glucose uptake. Thus, the metastasised tumour 
cells evade anoikis by upregulation of the TCA cycle [12]. 
Previous studies have reported upregulation of wild-type 
IDH2 in lung cancer, ovarian cancer, endometrioid carci-
noma, and advanced colorectal cancer [13, 14]. Gain of 
function mutations in IDH2 result in an increase in the onco-
metabolite 2-hydroxyglutarate (2-HG) which is believed to 
link aberrant metabolism and aberrant epigenetics and gene 
regulation in cancer [15]. A well-known function of mutant 
IDH2 has been demonstrated in cancers such as glioma, 
cholangiocarcinoma, and breast solid papillary carcinoma 
with reverse polarity (SPCRP) [16]. Wild-type IDH2 over-
expression is an indicator of poor outcome in lung cancer 
through the stimulation of the Warburg effect to help the 
maintenance of cancer cells via activation of hypoxia induc-
ible factor 1α (HIF1α) which supports tumour growth in 
hypoxic environments [17]. However, the role of wild-type 
IDH2 in BC is still unclear. In this study, we aimed to assess 
the expression of wild-type IDH2 in BC and evaluate its 
role in tumour progression, particularly LVI, and patient 
outcome.
Materials and methods
IHD2 protein expression
Study cohorts
Large well-characterised BC cohorts consisting of pure 
ductal carcinoma in situ (DCIS; n = 776) and invasive 
disease (IBC; n = 859) from patients presented between 
1998 and 2006 at Nottingham City Hospital, Nottingham, 
United Kingdom (UK) as previously described [18, 19] 
were utilised in this study. Patients’ demographic data, 
tumours’ morphological features, treatment data including 
surgery, hormonal therapy, radiotherapy and chemotherapy 
were available for both cohorts. Patients receiving neo-
adjuvant therapy were excluded in this study. Oestrogen 
Receptor (ER), Progesterone Receptor (PgR), HER2 status 
and Ki67 data was available [20, 21]. As per previous pub-
lications [20, 22, 23], ER and PgR was defined as ≥ 1%. 
HER2 positivity was defined when ≥ 10% of tumour cells 
showed strong membranous staining (score + 3), where 
chromogenic in situ hybridisation technique (CISH) was 
used to assess the gene amplification status in border-
line cases (+2). BC molecular subtypes (for both DCIS 
and IBC cohorts) including luminal A (ER+/HER2−; 
Ki67 < 10%), Luminal B (ER+/HER2−; Ki67⩾10%), 
HER2-positive class (HER2+ regardless of ER status), 
and TN (ER−, PgR− and HER2 −) were defined based on 
IHC profile. For further understanding the molecular inter-
actions of IDH2, available data on basal phenotype (CK5, 
CK14, and EGFR), EMT related markers (E-cadherin, 
N-cadherin, P-cadherin, TGF beta, and TWIST2), and glu-
tamine metabolism proteins (SLC1A5, SLC3A2, SLC7A5, 
GLS, ALDH18A1, ALDH4A1, PRODH) were included in 
this study as per previous publications [24–28].
The patient records were regularly updated includ-
ing patient’s outcome and follow-up. Local recurrence 
free interval (LRFI) in DCIS was defined as the time (in 
months) between 6 months after the first DCIS surgical 
removal and the occurrence of ipsilateral local recurrence. 
Patients had close/positive surgical margins or presented 
with residual tumour tissue and undergoing re-excision 
surgery within the first 6 months were not considered as 
recurrence. Patients who developed contralateral breast 
event after initial diagnosis of DCIS were censored at the 
time of occurrence of the contralateral disease. For IBC, 
data on breast cancer-specific survival (BCSS) was defined 
as the period (in months) extending from the date of pri-
mary surgery to the time of death due to breast cancer, 
and time to distant metastasis (TTDM) was defined as the 
period (in months) from primary surgery to occurrence of 
first distant metastasis.
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Immunohistochemistry (IHC)
Twenty full face BC tissue sections (including DCIS 
and IBC) based on different tumour grades, LVI status 
and histological type were stained using IHC to evaluate 
the pattern of IDH2 protein expression prior to staining 
of Tissue Microarrays (TMAs). TMAs were previously 
prepared using a TMA Grand Master® (3D HISTECH®, 
Budapest, Hungary) [19, 26].
Primary antibody specificity for the mouse monoclo-
nal anti-wild-type IDH2 antibody (ab55271, Abcam, UK) 
was validated using Western blot. An array of breast can-
cer cell line lysates was used, which include MCF-10A, 
MCF7, and MB-MDA-231 (obtained from the American 
Type Culture Collection, Rockville, MD, USA). IDH2 
antibody was used at a dilution of 1:500, which showed a 
single specific band at the predicted molecular weight of 
47 kDa (Supplementary Fig. 1).
Antigen retrieval was performed based on the manufac-
turer’s recommendations (citrate buffer pH 6.0 at 1000 W 
for 20 min using microwave). Expression of IDH2 protein 
was assessed by IHC using the Novocastra Novolink™ 
Polymer Detection Systems kit (Code: RE7280-K, Leica, 
Biosystems, UK), where 4 µm sections were incubated for 
60 min with mouse monoclonal IDH2 (dilution 1:500). 
Normal kidney tissue was used as a positive control, 
while a negative control was carried out by omitting the 
primary antibody.
Scoring of IDH2 expression
Assessment of IDH2 cytoplasmic expression was per-
formed using the semi-quantitative Histochemical score 
(H-score), where staining intensity was multiplied by the 
percentage of representative cells in the tissue for each 
intensity, producing a range of values between 0 and 300 
[29]. All non-representative cores (folded tissue during 
processing and staining or cores with only normal breast 
tissue or those containing < 15% tumour cells relative 
to the whole core area) were excluded from scoring. 
The scoring was performed by AA blinded to patients’ 
clinicopathological and outcome, with a subset of cores 
(~ 10%) scored independently by another scorer (MAA) 
to calculate the inter-observer concordance. The protein 
expression of IDH2 was dichotomised by cut-off points 
generated from X-tile bioinformatics software version 
3.6.1 (Yale University, USA) based on BCSS in IBC and 
LRFI in DCIS. An H-score of 70 was the optimal cut-off 
value of IDH2 protein expression in IBC, while a H-score 
of 45 was used to dichotomise DCIS cases into high and 
low expression.
IDH2 transcriptomic analysis
Two datasets comprising the METABRIC (n = 1980) [6] and 
TCGA breast carcinoma (TCGA BRCA, n = 854) [30] were 
used to evaluate IDH2 mRNA expression. The median was 
used as cut-off to categorise mRNA expression levels into 
high and low subgroups. For further validation of the prog-
nostic significance of IDH2 expression in BC, the prognostic 
analytical module within the publicly available online data-
set of Breast Cancer Gene Expression Miner v4.0 (http://
bcgen ex.centr egaud uchea u.fr) was used.
Statistical analysis
Statistical analysis was performed using SPSS, version 24 
(Chicago, IL, USA). The interclass correlation coefficient 
(ICC) test was used to assess the concordance rate of the 
IDH2 scoring between both the observers. The associa-
tion between IDH2 and various clinicopathological param-
eters in both cohorts was analysed using Chi-square test. 
Mann–Whitney test was used to compare between IDH2 
expression in DCIS and IBC. The Spearman’s rank correla-
tion coefficient was used to assess the correlation between 
IDH2 mRNA and protein expression levels in IBC.
Log rank test and Kaplan–Meier curves were used for 
univariate survival analysis. Analysis with recurrence in 
DCIS was carried out for the breast conservative surgery 
(BCS) treated group (and not for those treated by mastec-
tomy). Cox regression model was used for multivariate anal-
ysis. For all tests, a two-tailed p value < 0.05 was considered 
as statistically significant.
Results
Patterns of IDH2 protein expression
The full face tissue sections demonstrated an even staining 
of IDH2 expression within IBC and DCIS, indicating that 
TMA cores are representative for the whole tumour when 
assessing IDH2 expression. Adjacent normal breast termi-
nal duct-lobular units showed occasional weak cytoplasmic 
staining. Occasional stained inflammatory cells and stromal 
fibroblasts were evident in a few cores. When present, IDH2 
was expressed in the cytoplasm of epithelial tumour cells 
(Fig. 1). After exclusion of uninformative cores, 512 and 
859 cases were available to evaluate the immunoreactivity 
in DCIS and IBC, respectively. There was a strong con-
cordance between both observers in IDH2 immunoscoring 
(ICC = 0.855, p < 0.001). Distribution of IDH2 expression 
showed unimodal distribution. High IDH2 expression was 
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observed in 49% and 59% of pure DCIS and IBC cases, 
respectively. IDH2 expression was higher in IBC than DCIS 
(Z = 9.5, p < 0.0001).
Significance of IDH2 protein expression
In pure DCIS, numerous clinicopathological parameters indi-
cating poor DCIS prognosis were associated with high IDH2 
expression (Table 1) including younger age at diagnosis, 
(p = 0.035), larger tumour size, higher nuclear grade (both 
p < 0.0001), presence of comedo type necrosis (p = 0.001), 
hormonal receptor negativity and HER2 positivity (all 
p < 0.0001). In IBC, high IDH2 protein expression was asso-
ciated with positive LVI status (p = 0.002), high histological 
grade, high Nottingham Prognostic Index (NPI), hormonal 
receptor negativity, HER2 positivity (all p < 0.0001), large 
tumour size (p = 0.005), basal phenotype (p = 0.007) and 
high proliferation index (Ki67) (p = 0.008) (Table 2). There 
was positive correlation between IDH2 protein expression 
and the expression of EGFR (p < 0.0001), CK5 (p = 0.003), 
EMT markers including E-cadherin (p = 0.003), N-cadherin, 
P-cadherin and TWIST2 (all p < 0.0001). There was a posi-
tive correlation between IDH2 and enzymes within the glu-
tamine-proline regulatory axis: GLS (p < 0.001), PRODH 
Fig. 1  Photomicrographic images (× 40) for immunohistochemical 
protein expression of IDH2 in breast tissue microarray images; a nor-
mal breast terminal duct-lobular showing negative to faint staining, b 
negative expression in invasive breast carcinoma, c positive expres-
sion in invasive breast carcinoma, and d positive expression in DCIS
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(p = 0.010), ALDH4A1 (p = 0.012), and solute transporters 
including SLC1A5 (p = 0.002), SLC3A2 and SLC7A5 (both; 
p < 0.001). Correlation matrix of IDH2 with other associated 
proteins in IBC is shown in Fig. 2.
IDH2 protein expression and patient outcome
Survival analysis in DCIS revealed that higher IDH2 expres-
sion was correlated with shorter LRFI for all recurrences 
(HR = 2.4, 95% CI 1.3–4.5, p = 0.005, Fig. 3a) and a trend 
for association with shorter LRFI for invasive recurrences 
(HR = 1.9, 95% CI 0.9–4.4, p = 0.07 Fig. 3b) in patients 
treated solely with BCS without adjuvant radiotherapy. Mul-
tivariate survival analysis revealed that a high expression of 
IDH2 was an independent poor prognostic factor for DCIS 
recurrence (HR 2.0; 95% CI 1.1–3.9; p = 0.034) regardless of 
Table 1  Statistical associations between IDH2 protein expression 
with clinicopathological parameters in the pure ductal carcinoma 
in situ cohort
Significant p values are in bold
Clinicopathological parameters IDH2 expression χ2
(p value)Low 
(N = 261) 
N (%)
High 
(N = 251) 
N (%)
Age (years) 4.4
(0.035) ≤ 50 22 (8) 36 (14)
 > 50 239 (90) 215 (86)
DCIS size (mm) 22.5
(< 0.0001) ≤ 20 157 (61) 101 (40)
 > 20 99 (39) 150 (60)
Nuclear grade 18.8
(< 0.0001) Low 49 (19) 20 (8)
 Moderate 74 (28) 56 (22)
 High 138 (53) 175 (70)
Comedo necrosis 10.5
(0.001) No 114 (44) 75 (30)
 Yes 147 (56) 176 (70)
Oestrogen receptor 12.0
(0.001) Negative 36 (18) 74 (33)
 Positive 160 (82) 148 (67)
Progesterone receptor 18.0
(< 0.0001) Negative 54 (30) 115 (50)
 Positive 129 (70) 114 (50)
HER2 status 12.7
(< 0.0001) Negative 172 (86) 157 (72)
 Positive 28 (14) 62 (28)
Molecular classes 20.1
(< 0.0001) Luminal A 89 (63) 75 (39)
 Luminal B 23 (16) 47 (24)
HER2 enriched 9 (6) 29 (15)
 Triple negative 20 (15) 42 (22)
Table 2  Statistical associations between IDH2 protein expression and 
the clinicopathological factors in invasive breast cancer cohort
Significant p values are in bold
Clinicopathological parameters IDH2 expression χ2
(p value)Low 
(N = 349) 
N (%)
High 
(N = 510) 
N (%)
Age (years) 3.526
(0.060) ≤ 50 113 (37) 197 (63)
 > 50 234 (43) 310 (57)
Tumour size (cm) 7.787
(0.005) ≤ 2 199 (45) 241 (55)
 > 2 148 (36) 256 (64)
Tumour grade 41.664
(< 0.0001) Low 71 (55) 59 (45)
 Moderate 140 (51) 135 (49)
 High 138 (30) 314 (70)
Tumour stage 1.723
(0.632) Low 224 (41) 316 (59)
 Moderate 98 (40) 150 (60)
 High 27 (39) 42 (61)
Nottingham Prognostic Index 21.763
(< 0.0001) Poor 45 (33) 93 (67)
 Moderate 169 (37) 293 (63)
 Good 133 (53) 120 (47)
LVI status 9.552
(0.002) Negative 250 (45) 311 (55)
 Positive 97 (34) 192 (66)
Nodal status 0.262
(0.609) Negative 222 (41) 315 (59)
 Positive 125 (40) 191 (60)
Oestrogen receptor 25.640
(< 0.0001) Negative 55 (26) 158 (74)
 Positive 292 (46) 350 (54)
Progesterone receptor 18.100
(< 0.0001) Negative 111 (32) 236 (68)
 Positive 229 (47) 262 (53)
HER2 status 9.627
(0.002) Negative 312 (43) 415 (57)
 Positive 28 (27) 76 (73)
Molecular classes 33.632
(< 0.0001) Luminal A 109 (53) 95 (47)
 Luminal B 122 (44) 158 (56)
HER2 enriched 28 (27) 76 (73)
 Triple negative 43 (28) 112 (72)
Basal phenotypes
 Negative 272 (43) 366 (57) 7.360
(0.007) Positive 63 (32) 135 (68)
Ki67
 Negative 127 (47) 142 (53) 7.131
(0.008) Positive 156 (37) 266 (63)
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the other variables including patient age at diagnosis, DCIS 
size, nuclear grade, presence of comedo necrosis and surgi-
cal margin width (Table 3).
Comparable results were obtained in IBC where high 
IDH2 protein expression was associated with shorter BCSS 
(HR 1.6; 95% CI 1.2–2.2; p = 0.003; Fig. 4). High expres-
sion of IDH2 however was not associated with the distant 
metastasis (HR 1.1; 95% CI 0.9–1.4; p = 0.310; Supplemen-
tary Fig. 2). When the cohort was split into the intrinsic 
molecular subtypes, high expression of IDH2 protein in 
luminal B-like was associated with poor outcome in LVI 
positive tumours (HR 2.1; 95% CI 1.0–4.5; p = 0.044; Sup-
plementary Fig. 3a). HER2 positivity was in borderline asso-
ciation with overexpression of IDH2 in LVI positive status 
(p = 0.062; Supplementary Fig. 3b), but not with TN subtype 
defined as ER−, PR−, HER2− (p = 0.221; Supplementary 
Fig. 3c).
In multivariate Cox regression analysis, high IDH2 pro-
tein expression was an independent predictor of shorter 
BCSS (HR 1.4; 95% CI 1.1–1.9; p = 0.042) regardless of the 
tumour grade, lymph node stage and nodal status (Table 4).
IDH2 mRNA expression
High IDH2 mRNA expression was observed in 50% of IBC 
in the METABRIC and TCGA datasets, respectively. There 
was a significant positive linear correlation between IDH2 
protein expression and IDH2 mRNA expression (r = 0.240, 
p = 0.002) when tested in the Nottingham subset of the 
METABRIC cases (n = 288). Similar to IDH2 protein, in 
the METABRIC and TCGA datasets, overexpression of 
IDH2 mRNA was significantly associated with LVI-posi-
tivity (all; p = 0.001). In both datasets, high expression of 
IDH2 mRNA was associated with high histological grade 
and hormonal receptor negativity (both; p < 0.0001). Moreo-
ver, in the METABRIC cohort, high IDH2 mRNA levels 
were associated with large tumour size (p = 0.038), axillary 
lymph node positivity and HER2 positivity (all; p < 0.0001); 
(Table 5). In the METABRIC cohort, BCSS of patients with 
Fig. 2  Correlation matrix showing the association between IDH2 pro-
tein expression and with other biomarkers related to cellular prolif-
eration, metabolism and epithelial mesenchymal transition. Positive 
correlation is displayed in blue colour and negative correlation in red 
colour. Colour intensity is proportional to the correlation coefficient
Fig. 3  Kaplan–Meier survival plots showing that higher expression of IDH2 is associated with shorter local recurrence free interval in DCIS 
patients treated with breast conserving surgery for all recurrences (a) and a trend with invasive recurrences (b)
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high IDH2 mRNA expression was significantly shorter 
than those with low expression (HR 1.38; 95% CI 1.2–1.6; 
p < 0.0001) (Fig. 5a), but not in TCGA dataset (HR = 1.0; 
95% CI 0.7–1.5; p = 0.916); (Fig. 5b). External validation 
using the Gene Miner datasets (n = 4039) of IDH2 further 
supported that high expression of IDH2 mRNA was posi-
tively associated with shorter patient outcome (HR 1.26; 
95% CI 1.1–1.4; p = 0.0002), Supplementary Fig. 4.
Discussion
Breast cancer represents a group of heterogeneous diseases 
that vary in their morphological, molecular, and clinical 
behaviour. This heterogeneity poses challenges in precise 
understanding of the biology of BC, and hence to define a 
personalised therapy approach [31].
Despite the breakthrough of the genetic and molecular 
analysis, the mechanisms underlying progression of breast 
in situ lesions into invasive disease, and those involved in 
distant metastasis and LVI are still to be defined. Wild-type 
IDH2 was previously described as a key factor in DCIS 
progression into invasive disease [9, 10], and controlling 
LVI [8]. However, the prognostic significance of IDH2 in 
breast cancer has not been described before. To the best of 
our knowledge, this is the first study addressing the role of 
wild-type IDH2 protein in BC using IHC and well annotated 
cohort of patients.
The current study included large cohorts of pre-invasive 
and IBC to assess the transcriptomic and proteomic expres-
sion of IDH2 expression and its correlation with the clinico-
pathological parameters and patients’ outcome. Our analysis 
of IDH2 expression in DCIS supported our hypothesis that 
this protein would be associated with features of high-risk 
DCIS. In addition, the poor prognostic significance of higher 
IDH2 expression was independent from other clinical and 
morphological features, and with a trend of association 
towards invasive recurrence and progression.
Similarly, results in IBC showed that a high IDH2 expres-
sion was associated with criteria of aggressive behaviour 
including LVI, larger tumour size, higher grade and poor 
NPI. This supports the results of previous studies which 
demonstrated that IDH2 is significantly associated with 
LVI [32]. High IDH2 expression was also an independent 
Table 3  Multivariate Cox regression survival analysis of variables 
(with and without IDH2) predicting outcome in terms of ipsilateral 
local recurrences in all patients treated by breast conserving surgery 
in pure ductal carcinoma in situ cohort
Significant p values are in bold
Parameters Hazard 
ratio (HR)
95% confidence 
interval (CI)
p value
Lower Upper
Conventional clinicopathological parameters associated with high-
risk DCIS
 Patient age 0.3 0.1 0.5 0.0001
 DCIS size 1.6 0.9 2.7 0.055
 DCIS nuclear grade 1.8 1.2 2.7 0.002
 Comedo necrosis 0.6 0.4 1.1 0.096
 Margin status 0.8 0.7 0.9 0.012
Expression of IDH2 and other clinicopathological parameters asso-
ciated with high-risk DCIS
 IDH2 expression 2.0 1.1 3.9 0.034
 Patient age 0.2 0.1 0.4 < 0.0001
 DCIS size 1.6 0.8 3.3 0.224
 DCIS nuclear grade 1.3 0.8 2.4 0.315
 Comedo necrosis 1.5 0.7 3.3 0.345
 Margin status 0.8 0.7 0.9 0.039
Fig. 4  Kaplan–Meier survival plot showing high expression of IDH2 
protein is associated with shorter breast cancer-specific survival in the 
invasive breast cancer cohort
Table 4  Multivariate Cox regression for predictors of breast cancer-
specific survival and IDH2 protein expression in invasive breast can-
cer cohort
Significant p values are in bold
Parameter Hazard 
Ratio (HR)
95% confidence 
interval (CI)
p value
Lower Upper
IDH2 overexpression 1.4 1.1 1.9 0.040
Tumour grade 2.0 1.6 2.7 < 0.0001
Tumour stage 2.4 2.0 2.9 < 0.0001
Nodal Status 0.4 0.2 0.7 0.002
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predictor of shorter BCSS either in proteomic or transcrip-
tomic datasets. In METABRIC and bc-Exminer, datasets 
support the poor prognostic significance of high IDH2 
expression.
Cellular energy produced by the TCA cycle is upregu-
lated in highly proliferative and metastasised cancer cells. 
Energy metabolism and biosynthetic intermediates such as 
Alpha-ketoglutarate (αKG) produced through TCA from 
isocitrate by IDH2 is essential in tumour progression and 
metastasis. Wild-type IDH2 can reduce αKG and increase 
2-HG production, in turn disrupting normal epigenetic 
regulation of transcription [15]. For example, in hypoxic 
condition in BC, IDH2 carboxylates α-KG from glutamine 
to citrate and elevates 2-HG levels, acting as an oncome-
tabolite [33]. Moreover, when IDH2 reduces αKG, it can 
have an oncogenic impact on cellular differentiation [17]. 
αKG may have a role in the epithelial–mesenchymal transi-
tion (EMT), which is a key step during metastasis. It has 
been shown that blocking of αKG inhibits cellular transfor-
mation and cancerous cell invasion through transamination 
Table 5  Statistical 
association between IDH2 
mRNA expression and 
clinicopathological parameters 
in the METABRIC cohort 
of invasive breast cancer 
(n = 1980) and TCGA Breast 
Carcinoma cohort (n = 854)
Significant p values are in bold
Clinicopathological parameters METABRIC Cohort χ2 TCGA Cohort χ2
(p value)Low 
(N = 991)
N (%)
High 
(N = 989)
N (%)
(p value) Low 
(N = 427)
N (%)
High 
(N = 427)
N (%)
Age (years) 8.249
 ≤ 50 186 (44) 238 (56) (0.004) 322 (52) 301 (48) 2.617
(0.106) > 50 805 (52) 751 (48) 105 (45) 126 (55)
Tumour size (cm) 4.300
(0.038) ≤ 2 333 (53) 289 (47) 302 (49) 313 (51) 0.703
(0.402)
 > 2 649 (48) 689 (52) 125 (52) 114 (48)
Tumour grade 151.170
(< 0.0001) Low 116 (68) 54 (32) 63 (71) 26 (29) 73.783
(< 0.0001) Moderate 484 (63) 286 (37) 228 (61) 147 (39)
 High 340 (36) 612 (64) 116 (33) 236 (67)
LVI status
 Negative 505 (54) 425 (46) 11.663
(0.001)
303 (54) 256 (46) 11.440
(0.001)
 Positive 289 (45) 346 (55) 124 (42) 171 (58)
Nodal status
 Negative 557 (54) 478 (46) 12.852
(< 0.0001)
214 (50) 212 (50) 0.029
(0.864)
 Positive 429 (46) 509 (54) 210 (50) 213 (50)
Oestrogen receptor
 Negative 109 (23) 365 (77) 182.459
(< 0.0001)
51 (28) 134 (72) 45.967
(< 0.0001)
 Positive 882 (59) 624 (41) 357 (56) 282 (44)
Progesterone receptor 583 (62) 104.319
(< 0.0001)
89 (33) 183 (67) 45.957
(< 0.0001)
 Negative 357 (38) 316 (58)
 Positive 634 (61) 406 (39) 230 (42)
HER2 status 123.275
(< 0.0001) Negative 949 (55) 784 (45) 305 (54) 262 (46) 19.848
(< 0.0001) Positive 42 (17) 205 (83) 43 (32) 0 (68)
Molecular classes 279.615
(< 0.0001)
Not available
 Luminal A 457 (64) 261 (36)
 Luminal B 287 (59) 201 (41)
HER2 enriched 30 (12.5) 210 (88)
 Basal like 92 (28) 237 (72)
 Normal like 124 (62) 75 (38)
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or reverse TCA cycle [12, 34]. Our data shows that IDH2 
is associated with EMT proteins and factors including in 
cellular metabolism and energy production, which support 
its role in disease progression and metastasis. This study 
showed that high IDH2 protein was significantly associated 
with EGFR which can regulate epithelial mesenchymal 
transition (EMT), migration and invasion [35]. Moreover, 
this study also demonstrates that high N-cadherin is asso-
ciated with high IDH2 protein. Previous studies elucidate 
that N-cadherin has a role in motility, invasion and metas-
tasis by increasing MMP-9 production allowing tumour 
cells to penetrate the matrix barriers and to adhere to the 
endothelium. This may also increase the chance of tumour 
cells to enter and exit the vasculature [36]. Additionally, it 
has been reported that N-cadherin can induce EMT which 
plays a fundamental role in the invasion and metastasis of 
cancer cells [37]. Thus, the observed association between 
the high levels of IDH2 and N-cadherin explain the role 
of IDH2 in LVI as N-cadherin can promote two properties 
of the metastasised cell i.e. adhesion and invasion. IDH2 
was also associated with TWIST2 EMT marker. EMT has 
a highly important role in cancer invasion and metastasis. 
In BC and lymph node metastases, Twist2 is overexpressed 
as it results in morphological transformation, downregula-
tion of epithelial markers and upregulation of mesenchymal 
markers [38]. Thus, Interaction with EMT markers explains 
the role of IDH2 in DCIS progression into invasive disease 
and invasion of BC cells through the lymphovascular chan-
nels. EMT is a known mechanism attained by the breast 
carcinoma cells for basement membrane invasion and LVI 
[39]. Further mechanistic studies are highly warranted to 
understand the underlying molecular mechanisms.
Additionally, one of the major hallmarks of cancer is 
reprogramming energy metabolism [40]. High rates of 
glucose and glutamine are taken up by cancer cells to pro-
duce NADPH to survive and grow followed by decreasing 
the level of intracellular αKG [41]. Many studies provide 
evidence that oncogenes can alter cancer cell metabolism 
including glutamine transporters which were associated 
with high IDH2 in this study [26]. This may imply that 
IDH2 could potentially re-programme the metabolic path-
ways in BC and support tumour cells to survive and indi-
cate its prognostic significance in BC. Our observations 
showed that high IDH2 was associated with high grade 
DCIS and IBC with a highly proliferative index. High 
expression of IDH2 was associated with EGFR, CK5 and 
CK14 which are connected to the highly proliferative basal 
phenotype [42, 43]. In this study, IDH2 was also associ-
ated with high Ki67 expression reflecting increased cel-
lular proliferation [44]. It has been reported that IDH2 has 
a critical role in cell proliferation through the alteration of 
NADP levels. Beside the role of NADP as antioxidants, it 
has been reported that NADP has an important role in cell 
death. It links cell survival with biological properties such 
as energy metabolism and oxidative stress, which are fac-
tors that determine cell death [14]. Primary tumour cells 
must proliferate and invade the adjacent tissue to estab-
lish an invasion and metastasis cascades, which consists 
of many steps including basement membrane degradation 
and LVI. Proliferation lasts until the invasion of blood 
vessels or lymphatic channels occur. Tumour cells at this 
stage evade apoptosis and immune responses [45]. Thus, 
IDH2 may have an important role in cell proliferation, 
which is a perquisite step of the invasion and metastatic 
Fig. 5  Kaplan–Meier survival plots showing the association between mRNA IDH2 and breast cancer-specific survival in (a) METABRIC cohort 
and (b) TCGA dataset
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process, which can lead to the development of invasive 
cancer from a pre-invasive lesion, and for development of 
LVI and hence distant metastasis.
Furthermore, IDH2 mRNA and protein were also highly 
expressed in TNBC and HER2+ either in IBC or DCIS, 
in concordance with previous studies [5]. HER2+ tumours 
were more likely to have IDH2 protein which is perhaps 
unsurprising as high grade progressing DCIS and LVI are 
significantly associated with HER2 positivity [1]. It also has 
been shown that tumour microenvironment plays a major 
role in the HER2 signalling pathway, invasion and the devel-
opment of LVI, which is a crucial step in metastasis [46]. 
IDH2 high expression might enhance HER2 signalling path-
ways that can have effect on the tumour microenvironment 
to support the growth of the tumour cell, stimulating inva-
sion, LVI and metastasis in BC. The molecular subtypes 
differ from each other in their expression of claudin [47]. 
For example, low expression of the claudin tight junction 
protein and the high expression of proteins involved in EMT 
and cancer cell invasiveness were reported in TN compared 
to other subtypes [48]. This could explain the difference in 
the significance between these subtypes.
This study reveals that IDH2 is associated with poor 
prognostic characteristics and short-term survival outcomes 
in BC including higher local recurrence rate after diagno-
sis of DCIS or poor survival rate in IBC. Furthermore, a 
positive association of IDH2 and elevated levels of basal 
cytokeratin confers a poor prognosis. Basal cytokeratins are 
strongly associated with high histological grade, negative 
hormone status and worse patient outcome [39, 49]. Among 
subgroups, overexpression of IDH2 protein appears to play 
a particularly significant role in luminal B subtype which is 
in concordance with a recent study [50].
In conclusion high expression of IDH2 is an independent 
poor prognostic factor in BC. High expression of IDH2 may 
have a key role in BC progression from DCIS to IBC and in 
the development of LVI and metastasis. Further functional 
assessment of IDH2 in BC is warranted to detect its underly-
ing mechanistic roles and its therapeutic potential.
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